X
Pharma Advancement
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development

    Nasal Spray Shows Its Effect Against New COVID Variants

    Mid-Point Regulatory Science Strategy Study Published By EMA

    AADC Inadequacy To Be Handled By A Novel Gene Therapy

    New Drug Explored For Epilepsy Gets $3M Funding In Australia

    Care Access Research Launches Alliance to Provide Infrastructure for COVID-19 Trials

    Faster Clinical Trial Nods Planned By The UK To Curb Issues

    Pharma Drugs Gain From Tardigrade Proteins, Says Research

    Pharma Drugs Gain From Tardigrade Proteins, Says Research

    U.S. FDA Approves DARZALEX Split-Dosing Regimen

    EMA Keeping A Close Watch On Critical Medicine Shortages

    Pathways Laid Down By The CMS For Drug Price Negotiations

    Pathways Laid Down By The CMS For Drug Price Negotiations

    Efficacy Shown On Cystic Fibrosis Patients In 4-Year Study

  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development

    Nasal Spray Shows Its Effect Against New COVID Variants

    Mid-Point Regulatory Science Strategy Study Published By EMA

    AADC Inadequacy To Be Handled By A Novel Gene Therapy

    New Drug Explored For Epilepsy Gets $3M Funding In Australia

    Care Access Research Launches Alliance to Provide Infrastructure for COVID-19 Trials

    Faster Clinical Trial Nods Planned By The UK To Curb Issues

    Pharma Drugs Gain From Tardigrade Proteins, Says Research

    Pharma Drugs Gain From Tardigrade Proteins, Says Research

    U.S. FDA Approves DARZALEX Split-Dosing Regimen

    EMA Keeping A Close Watch On Critical Medicine Shortages

    Pathways Laid Down By The CMS For Drug Price Negotiations

    Pathways Laid Down By The CMS For Drug Price Negotiations

    Efficacy Shown On Cystic Fibrosis Patients In 4-Year Study

  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home Manufacturing

Sirio Europe invest in advanced manufacturing and green technologies at Brandenburg site

Content Team by Content Team
21st October 2020
in Manufacturing, News
Sirio Europe invest in advanced manufacturing and green technologies at Brandenburg site

Sirio Europe – the leading European nutraceutical and pharmaceutical contract development and manufacturing organisation (CDMO), part of the Sirio group – announces the completion of a major overhaul of its Brandenburg site with advanced manufacturing and green technologies. The company has installed new HVAC systems, individual drying chambers, vegetarian softgel manufacturing equipment and a block heat & power plant. The improvements were implemented as part of Sirio Europe’s continuous efforts to further improve the quality and sustainability of manufacturing.

“One of the reasons behind the investments was that we wanted to be at the forefront of implementing greener solutions and energy-efficient manufacturing for our pharma customers. So while implementing new equipment, we also explored how we can improve the plant’s sustainability.” commented Dominique Baum, Managing Director at Sirio Europe

The HVAC systems increase the plant’s manufacturing capacity while further reducing the risk of product contamination. Similarly, by using only individual drying chambers, the company can control the temperature of individual products, which is more energy-efficient and improves the softgel drying process. Additionally, a new vegetarian softgel manufacturing line has been installed – transferring technology from Sirio’s Guangzhou plant – in response to the growing demand for plant-based nutraceuticals.

But in line with the company commitment to increased sustainability, the site upgrades will be supported by an energy-efficient block heat & power station, which is estimated to increase power output by up to 50% through combined heat and power (CHP). The technology captures and recycles heat – otherwise lost as waste – into thermal energy to power the new manufacturing equipment.

Baum added: “Installing the heat block & power station is a huge business benefit in terms of reducing energy consumption. For example, softgel production uses a lot of energy as strict parameters need to be adhered to – through CHP we can now manufacture softgels at a lower cost. But installing the heat block was also the right thing to do in terms of looking at ways to make manufacturing as sustainable as possible”.

The new plant upgrades form just a small part of wider drive at the Sirio Group to implement the most sustainable manufacturing processes of any nutraceutical CDMO globally. For example, the company exclusively sources ingredients from certified, sustainable suppliers, and are members of a number of certified sustainability groups, including the Friends of the Sea (part of the World Sustainability Organisation) and Marine Stewardship Council.

About the Ayanda plant

Ayanda belongs to Sirio Europe, the European based member of Sirio Group with more than 20 years of experience in contract manufacturing of nutraceutical and pharmaceutical private label softgel products, that not only comply with but exceed industry standards and expectations.

Ayanda’s core business is development and manufacturing of complex softgels containing up to 10 or more ingredients. The company has a strict focus on quality and is dedicated to exceeding global quality requirements.

Ayanda is a Pharma GMP approved site, holds IFS Food Standard and BRC certifications, both graded at highest score. Since sustainability matters more and more to customers and consumers, Ayanda is organic certified and holds two certificates for sustainable seafood: FOS (Friend of the Sea) and MSC (Marine Stewardship Council).

About SIRIO

Founded in 1993, Sirio Pharma Co., Ltd (SIRIO) is the leading global nutraceutical CDMO specialized in developing and manufacturing quality products including softgel, capsule, tablet, powder, gummy, oral liquid, probiotics and other dosage forms. The company has extensive capabilities with multiple manufacturing sites in China, as well as manufacturing facilities in Europe and marketing teams in the USA. SIRIO is devoted to offering one-stop solutions including product developing, manufacturing, packaging and logistics to its customers.

SIRIO is approved by TGA-GMP, NPA/UL GMP, BRC, UL’s Management System 21 CFR Part 111, ISO 9001:2015 certification, and etc. Cooperating with many well-known nutraceutical companies, SIRIO is committed to providing products and service to customers all around the world.

Previous Post

ATMPS advanced therapy blockchain platform has successful testing with NHS partners

Next Post

New Functionality Added to Thermo Scientific SampleManager LIMS software for Manufacturing QA/QC and Contract Laboratories

Related Posts

Drug Development

Nasal Spray Shows Its Effect Against New COVID Variants

27th March 2023
FDA Approvals

Mid-Point Regulatory Science Strategy Study Published By EMA

27th March 2023
Drug Development

AADC Inadequacy To Be Handled By A Novel Gene Therapy

24th March 2023
Drug Development

New Drug Explored For Epilepsy Gets $3M Funding In Australia

23rd March 2023
Care Access Research Launches Alliance to Provide Infrastructure for COVID-19 Trials
Clinical Trials

Faster Clinical Trial Nods Planned By The UK To Curb Issues

22nd March 2023
Pharma Drugs Gain From Tardigrade Proteins, Says Research
Drug Development

Pharma Drugs Gain From Tardigrade Proteins, Says Research

22nd March 2023
Next Post
Thermo Scientific SampleManager LIMS software

New Functionality Added to Thermo Scientific SampleManager LIMS software for Manufacturing QA/QC and Contract Laboratories

Latest News

Drug Development

Nasal Spray Shows Its Effect Against New COVID Variants

27th March 2023
FDA Approvals

Mid-Point Regulatory Science Strategy Study Published By EMA

27th March 2023
Drug Development

AADC Inadequacy To Be Handled By A Novel Gene Therapy

24th March 2023
Drug Development

New Drug Explored For Epilepsy Gets $3M Funding In Australia

23rd March 2023
Care Access Research Launches Alliance to Provide Infrastructure for COVID-19 Trials
Clinical Trials

Faster Clinical Trial Nods Planned By The UK To Curb Issues

22nd March 2023
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack

System

  • Search
  • Sitemap
  • RSS Feed

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In